351 related articles for article (PubMed ID: 32638417)
1. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
Connelly MA; Velez Rivera J; Guyton JR; Siddiqui MS; Sanyal AJ
Aliment Pharmacol Ther; 2020 Aug; 52(4):619-636. PubMed ID: 32638417
[TBL] [Abstract][Full Text] [Related]
2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
3. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
4. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
5. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
[TBL] [Abstract][Full Text] [Related]
6. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
7. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
[TBL] [Abstract][Full Text] [Related]
8. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
[TBL] [Abstract][Full Text] [Related]
9. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.
Polyzos SA; Kechagias S; Tsochatzis EA
Aliment Pharmacol Ther; 2021 Oct; 54(8):1013-1025. PubMed ID: 34416040
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
11. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
12. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
14. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
Ogawa Y; Yoneda M; Kobayashi T; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A
Expert Opin Pharmacother; 2019 Jan; 20(1):69-82. PubMed ID: 30411635
[TBL] [Abstract][Full Text] [Related]
15. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
16. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment].
Pár A; Wittmann I; Pár G
Orv Hetil; 2022 May; 163(22):855-862. PubMed ID: 35895614
[TBL] [Abstract][Full Text] [Related]
17. Statins in liver disease: not only prevention of cardiovascular events.
Magan-Fernandez A; Rizzo M; Montalto G; Marchesini G
Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):743-744. PubMed ID: 29768950
[No Abstract] [Full Text] [Related]
18. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
19. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Hecht J; Tio F; Cusi K
J Clin Endocrinol Metab; 2017 Aug; 102(8):2950-2961. PubMed ID: 28575232
[TBL] [Abstract][Full Text] [Related]
20. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]